BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/24/2017 9:48:00 AM | Browse: 862 | Download: 1761
 |
Received |
|
2016-11-01 09:15 |
 |
Peer-Review Started |
|
2016-11-02 21:53 |
 |
To Make the First Decision |
|
2016-12-14 08:44 |
 |
Return for Revision |
|
2016-12-15 11:38 |
 |
Revised |
|
2016-12-20 02:18 |
 |
Second Decision |
|
2017-01-04 16:07 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2017-01-14 14:08 |
 |
Articles in Press |
|
2017-01-14 14:08 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2017-03-21 10:31 |
 |
Publish the Manuscript Online |
|
2017-03-24 09:48 |
ISSN |
1949-8470 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Radiology, Nuclear Medicine & Medical Imaging |
Manuscript Type |
Observational Study |
Article Title |
Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
|
Manuscript Source |
Invited Manuscript |
All Author List |
Amita Shukla-Dave, Cecilia Wassberg, Darko Pucar, Heiko Schöder, Debra A Goldman, Yousef Mazaheri, Victor E Reuter, James Eastham, Peter T Scardino and Hedvig Hricak |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Institutes of Health grant |
R01 CA76423 |
NIH/NCI Cancer Center Support Grant |
P30 CA008748 |
|
Corresponding Author |
Amita Shukla-Dave, PhD, Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,
United States. davea@mskcc.org |
Key Words |
Proton magnetic resonance spectroscopic imaging; <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography; Prostate cancer |
Core Tip |
Although metabolic imaging is increasingly utilized in prostate cancer (PCa), the mechanisms leading to cancer-related metabolic rearrangements and consequent imaging findings remain poorly understood. This study compared two modalities utilizing distinct metabolic pathways, proton magnetic resonance spectroscopic imaging (1H-MRSI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT), in local PCa. Abnormal intermediary metabolism on 1H-MRSI was present in 21/22 patients, while abnormal glycolysis on 18F-FDG-PET/CT was detected in only 3/22 patients. This study provides an insight why metabolic PET agents promising for detection of PCa target intermediary metabolism. On the other hand, elevated glycolysis may have ominous prognostic implications in PCa. |
Publish Date |
2017-03-24 09:48 |
Citation |
Shukla-Dave A, Wassberg C, Pucar D, Schöder H, Goldman DA, Mazaheri Y, Reuter VE, Eastham J, Scardino PT, Hricak H. Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer. World J Radiol 2017; 9(3): 134-142 |
URL |
http://www.wjgnet.com/1949-8470/full/v9/i3/134.htm |
DOI |
http://dx.doi.org/10.4329/wjr.v9.i3.134 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345